Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial
<br><strong>Background: </strong>Cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection continue to rise in the Arabian Peninsula 7 years after it was first described in Saudi Arabia. MERS-CoV poses a significant risk to public health security because of an abse...
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Médium: | Journal article |
| Jazyk: | English |
| Vydáno: |
Elsevier
2020
|
| _version_ | 1826309625801080832 |
|---|---|
| author | Folegatti, PM Bittaye, M Flaxman, A Lopez, FR Bellamy, D Kupke, A Mair, C Makinson, R Sheridan, J Rohde, C Halwe, S Jeong, Y Park, Y-S Kim, J-O Song, M Boyd, A Tran, N Silman, D Poulton, I Datoo, M Marshal, J Themistocleous, Y Lawrie, A Roberts, R Berrie, E Becker, S Lambe, T Hill, A Ewer, K Gilbert, S |
| author_facet | Folegatti, PM Bittaye, M Flaxman, A Lopez, FR Bellamy, D Kupke, A Mair, C Makinson, R Sheridan, J Rohde, C Halwe, S Jeong, Y Park, Y-S Kim, J-O Song, M Boyd, A Tran, N Silman, D Poulton, I Datoo, M Marshal, J Themistocleous, Y Lawrie, A Roberts, R Berrie, E Becker, S Lambe, T Hill, A Ewer, K Gilbert, S |
| author_sort | Folegatti, PM |
| collection | OXFORD |
| description | <br><strong>Background: </strong>Cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection continue to rise in the Arabian Peninsula 7 years after it was first described in Saudi Arabia. MERS-CoV poses a significant risk to public health security because of an absence of currently available effective countermeasures. We aimed to assess the safety and immunogenicity of the candidate simian adenovirus-vectored vaccine expressing the full-length spike surface glycoprotein, ChAdOx1 MERS, in humans.</br>
<br><strong>Methods: </strong>This dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial was done at the Centre for Clinical Vaccinology and Tropical Medicine (Oxford, UK) and included healthy people aged 18–50 years with negative pre-vaccination tests for HIV antibodies, hepatitis B surface antigen, and hepatitis C antibodies (and a negative urinary pregnancy test for women). Participants received a single intramuscular injection of ChAdOx1 MERS at three different doses: the low-dose group received 5 × 109 viral particles, the intermediate-dose group received 2·5 × 1010 viral particles, and the high-dose group received 5 × 1010 viral particles. The primary objective was to assess safety and tolerability of ChAdOx1 MERS, measured by the occurrence of solicited, unsolicited, and serious adverse events after vaccination. The secondary objective was to assess the cellular and humoral immunogenicity of ChAdOx1 MERS, measured by interferon-γ-linked enzyme-linked immunospot, ELISA, and virus neutralising assays after vaccination. Participants were followed up for up to 12 months. This study is registered with ClinicalTrials.gov, NCT03399578.</br>
<br><strong>Findings: </strong>Between March 14 and Aug 15, 2018, 24 participants were enrolled: six were assigned to the low-dose group, nine to the intermediate-dose group, and nine to the high-dose group. All participants were available for follow-up at 6 months, but five (one in the low-dose group, one in the intermediate-dose group, and three in the high-dose group) were lost to follow-up at 12 months. A single dose of ChAdOx1 MERS was safe at doses up to 5 × 1010 viral particles with no vaccine-related serious adverse events reported by 12 months. One serious adverse event reported was deemed to be not related to ChAdOx1 MERS. 92 (74% [95% CI 66–81]) of 124 solicited adverse events were mild, 31 (25% [18–33]) were moderate, and all were self-limiting. Unsolicited adverse events in the 28 days following vaccination considered to be possibly, probably, or definitely related to ChAdOx1 MERS were predominantly mild in nature and resolved within the follow-up period of 12 months. The proportion of moderate and severe adverse events was significantly higher in the high-dose group than in the intermediate-dose group (relative risk 5·83 [95% CI 2·11–17·42], p<0·0001) Laboratory adverse events considered to be at least possibly related to the study intervention were self-limiting and predominantly mild in severity. A significant increase from baseline in T-cell (p<0·003) and IgG (p<0·0001) responses to the MERS-CoV spike antigen was observed at all doses. Neutralising antibodies against live MERS-CoV were observed in four (44% [95% CI 19–73]) of nine participants in the high-dose group 28 days after vaccination, and 19 (79% [58–93]) of 24 participants had antibodies capable of neutralisation in a pseudotyped virus neutralisation assay.</br>
<br><strong>Interpretation: </strong>ChAdOx1 MERS was safe and well tolerated at all tested doses. A single dose was able to elicit both humoral and cellular responses against MERS-CoV. The results of this first-in-human clinical trial support clinical development progression into field phase 1b and 2 trials.</br> |
| first_indexed | 2024-03-07T07:37:01Z |
| format | Journal article |
| id | oxford-uuid:ce2e2ec2-9ec2-4a65-bd42-c92e6cf8f3ad |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:37:01Z |
| publishDate | 2020 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:ce2e2ec2-9ec2-4a65-bd42-c92e6cf8f3ad2023-03-20T10:33:40ZSafety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ce2e2ec2-9ec2-4a65-bd42-c92e6cf8f3adEnglishSymplectic ElementsElsevier2020Folegatti, PMBittaye, MFlaxman, ALopez, FRBellamy, DKupke, AMair, CMakinson, RSheridan, JRohde, CHalwe, SJeong, YPark, Y-SKim, J-OSong, MBoyd, ATran, NSilman, DPoulton, IDatoo, MMarshal, JThemistocleous, YLawrie, ARoberts, RBerrie, EBecker, SLambe, THill, AEwer, KGilbert, S<br><strong>Background: </strong>Cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection continue to rise in the Arabian Peninsula 7 years after it was first described in Saudi Arabia. MERS-CoV poses a significant risk to public health security because of an absence of currently available effective countermeasures. We aimed to assess the safety and immunogenicity of the candidate simian adenovirus-vectored vaccine expressing the full-length spike surface glycoprotein, ChAdOx1 MERS, in humans.</br> <br><strong>Methods: </strong>This dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial was done at the Centre for Clinical Vaccinology and Tropical Medicine (Oxford, UK) and included healthy people aged 18–50 years with negative pre-vaccination tests for HIV antibodies, hepatitis B surface antigen, and hepatitis C antibodies (and a negative urinary pregnancy test for women). Participants received a single intramuscular injection of ChAdOx1 MERS at three different doses: the low-dose group received 5 × 109 viral particles, the intermediate-dose group received 2·5 × 1010 viral particles, and the high-dose group received 5 × 1010 viral particles. The primary objective was to assess safety and tolerability of ChAdOx1 MERS, measured by the occurrence of solicited, unsolicited, and serious adverse events after vaccination. The secondary objective was to assess the cellular and humoral immunogenicity of ChAdOx1 MERS, measured by interferon-γ-linked enzyme-linked immunospot, ELISA, and virus neutralising assays after vaccination. Participants were followed up for up to 12 months. This study is registered with ClinicalTrials.gov, NCT03399578.</br> <br><strong>Findings: </strong>Between March 14 and Aug 15, 2018, 24 participants were enrolled: six were assigned to the low-dose group, nine to the intermediate-dose group, and nine to the high-dose group. All participants were available for follow-up at 6 months, but five (one in the low-dose group, one in the intermediate-dose group, and three in the high-dose group) were lost to follow-up at 12 months. A single dose of ChAdOx1 MERS was safe at doses up to 5 × 1010 viral particles with no vaccine-related serious adverse events reported by 12 months. One serious adverse event reported was deemed to be not related to ChAdOx1 MERS. 92 (74% [95% CI 66–81]) of 124 solicited adverse events were mild, 31 (25% [18–33]) were moderate, and all were self-limiting. Unsolicited adverse events in the 28 days following vaccination considered to be possibly, probably, or definitely related to ChAdOx1 MERS were predominantly mild in nature and resolved within the follow-up period of 12 months. The proportion of moderate and severe adverse events was significantly higher in the high-dose group than in the intermediate-dose group (relative risk 5·83 [95% CI 2·11–17·42], p<0·0001) Laboratory adverse events considered to be at least possibly related to the study intervention were self-limiting and predominantly mild in severity. A significant increase from baseline in T-cell (p<0·003) and IgG (p<0·0001) responses to the MERS-CoV spike antigen was observed at all doses. Neutralising antibodies against live MERS-CoV were observed in four (44% [95% CI 19–73]) of nine participants in the high-dose group 28 days after vaccination, and 19 (79% [58–93]) of 24 participants had antibodies capable of neutralisation in a pseudotyped virus neutralisation assay.</br> <br><strong>Interpretation: </strong>ChAdOx1 MERS was safe and well tolerated at all tested doses. A single dose was able to elicit both humoral and cellular responses against MERS-CoV. The results of this first-in-human clinical trial support clinical development progression into field phase 1b and 2 trials.</br> |
| spellingShingle | Folegatti, PM Bittaye, M Flaxman, A Lopez, FR Bellamy, D Kupke, A Mair, C Makinson, R Sheridan, J Rohde, C Halwe, S Jeong, Y Park, Y-S Kim, J-O Song, M Boyd, A Tran, N Silman, D Poulton, I Datoo, M Marshal, J Themistocleous, Y Lawrie, A Roberts, R Berrie, E Becker, S Lambe, T Hill, A Ewer, K Gilbert, S Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial |
| title | Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial |
| title_full | Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial |
| title_fullStr | Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial |
| title_full_unstemmed | Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial |
| title_short | Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial |
| title_sort | safety and immunogenicity of a candidate middle east respiratory syndrome coronavirus viral vectored vaccine a dose escalation open label non randomised uncontrolled phase 1 trial |
| work_keys_str_mv | AT folegattipm safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT bittayem safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT flaxmana safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT lopezfr safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT bellamyd safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT kupkea safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT mairc safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT makinsonr safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT sheridanj safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT rohdec safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT halwes safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT jeongy safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT parkys safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT kimjo safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT songm safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT boyda safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT trann safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT silmand safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT poultoni safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT datoom safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT marshalj safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT themistocleousy safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT lawriea safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT robertsr safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT berriee safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT beckers safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT lambet safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT hilla safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT ewerk safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial AT gilberts safetyandimmunogenicityofacandidatemiddleeastrespiratorysyndromecoronavirusviralvectoredvaccineadoseescalationopenlabelnonrandomiseduncontrolledphase1trial |